- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02373891
Study to Evaluate the Effect of Food on the Pharmacokinetics of Surfolase CR Tablet in Healthy Volunteers
Acebrophylline is metabolized by being separated into Ambroxol and 7-theophylline when orally administered as a salt composed of an acid-base as a compound that was synthesized by and chloride (salifying) the ambroxol to 7-theophylline. Acebrophylline is selectively applied to the bronchial or lung tissue and inhibit the activity of phospholipase bronchoalveolar shows the expectorant action to raise the surface activity of the alveolar, leukotrienes (LTs) and by suppressing the production of prostaglandins (PGs), showed potent anti-inflammatory activity, bronchial was celebrated by reducing the bronchial hyperreactivity to normal state is allowed to recuperate or extended.
It was developed to improve compliance improve pharmaceutically Acebrophylline that intake twice daily 100mg to Surfolase CR that intake once daily 200mg
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy male subjects between the ages of 20 and 55 years, BMI >18.5, <25, inclusive
*Body mass index(kg/m2) = weight(kg)/(height(m)2)
- Subject who don't have congenital or chronic diseases and have no abnormal medical examination results.
Subject is healthy (no clinically relevant findings in any of the investigations of the pre-examination) as judged by the investigator
- Hematology tests: WBC with differential count, RBC, Hemoglobin, Hematocrit, Platelet, PT(INR)/aPTT
- Blood chemistry tests: Calcium, Inorganic Phosphate, Fasting Glucose, BUN, Creatinine, Cholesterol, Total Protein, Albumin, Total Bilirubin, Alkaline phosphatase, AST, ALT, r-GT, LDH, TG, K, Na, Cl, uric acid, CPK
- Immune serum tests: HBsAg, anti-HCV Ab, anti-HIV Ag/Ab, β-hCG
- Urinalysis: Specific Gravity, pH, Protein, Glucose, Ketone, RBC, Urobilinogen, Bilirubin, Nitrite, WBC, Color, Turbidity, Sediment, Microscopy
- Urine drug screening tests: Amphetamine, Barbiturate, Morphine, Benzodiazepine, Cocaine 4) If you are a woman, you must be a negative pregnancy test at screening.
- Postmenopausal (no period for at least two years)
- Surgical sterilization (Hysterectomy or bilateral oophorectomy, tubal ligation)
- Before the screening, interfile male partner and this man is the sole partner of that person
Before Investigational product first dose administered at least 14 days before the start appropriate contraception until at least 28 days.
5) If you are a male and sexually active women of childbearing age, during the trial period contraception (condoms, etc.) and clinical trial duration, and IND maintaining adequate contraception up to 28 days after the last dose, and one party must agree that you will not donate sperm 6) Subjects who signed and dated in informed consent form indicating that the subject has decided to participate in the study after being informed of all pertinent aspects of the study
Exclusion Criteria:
- Subject with known for hypersensitivity reaction to acebrophylline, xanthine and food.
- Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Subject with serious active cardiovascular, respiratory, hepatologic, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease
- Subject with known for history of gastrointestinal disease or gastrointestinal surgery which affect on the absorption drug
- Subjects with any of the following condition in screening (blood pressure, 12-lead ECG, blood, urinalysis, etc.)
Subject with any of the following conditions in laboratory test
- AST or ALT > Upper normal limit × 1.25
- Total bilirubin > Upper normal limit × 1.5
If the estimated GFR < 80mL/min/1.73m2 using MDRD formula.
※ MDRD equation (mL/min/1.73m2)
: GFR = 175 x Scr-1.154 x age-0.203
- Systolic blood pressure <=90mmHg or diastolic blood pressure >=150mmHg or a person showing the corresponding figures <=50mmHg or >=100mmHg in vital signs.
- Who has history of drug abuse (especially hypnotic, central acting analgesics, psychotropic drugs, such as opiates or central nervous system acting drug) or shows positive reactions to drug of abuse in urine drug screening tests.
- Excessive caffeine and alcohol intake, smoking person(caffeine: > 5cups/day, alcohol: >210g/week, tobacco: > 10 cagarettes/day)
- Person cannot be non-smoking, non-alcohol during the hospital stay.
- Use of any prescription medication within 14 days prior to study medication dosing or use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing
- Participation in any clinical investigation within 60days prior to study medication dosing
- Subjects with whole blood donation within 60days, component blood donation within 30days
- Women who are pregnant or breast-feeding
- Person who cannot eat, including high-fat diet (more than 900kcal, containing more that 35% fat) that served during the trial period
- Person can not prohibit the consumption of grapefruit-containing food during the trial period.
- Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T1
|
T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m.
8:00
T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m.
8:00
|
Experimental: T0
|
T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m.
8:00
T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m.
8:00
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ambroxol AUClast, Cmax
Time Frame: Fasting medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36 h (17 times), Fat meal medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36h
|
Fasting medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36 h (17 times), Fat meal medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36h
|
Ambroxol AUCinf, Tmax, t1/2
Time Frame: Fasting medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36 h (17 times), Fat meal medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36h
|
Fasting medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36 h (17 times), Fat meal medication: 0 h (before intake), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 24, 36h
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Park, Severance Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HT-002-04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Surfolase CR
-
Hyundai Pharmaceutical Co., LTD.Completed
-
Hyundai Pharmaceutical Co., LTD.Completed
-
PfizerCompletedRheumatoid ArthritisUnited States
-
University of CalgaryUniversity of British Columbia; Alberta Health servicesRecruitingObesity | Atrial FibrillationCanada
-
Columbia UniversityNational Institutes of Health (NIH); National Center for Advancing Translational...SuspendedMyocardial Infarction | Acute Coronary SyndromeUnited States
-
Jing MaUnknownHeart Failure | Acute Myocardial InfarctionChina
-
University of North Carolina, Chapel HillCompleted
-
Zimmer BiometCompletedOsteoarthritis | Total Knee ArthroplastyUnited States
-
Beijing Anzhen HospitalBeijing Chao Yang Hospital; Beijing Luhe HospitalNot yet recruitingST-elevation Myocardial Infarction | Multivessel Coronary DiseaseChina
-
Centre for Addiction and Mental HealthCAMH FoundationActive, not recruitingMild Cognitive Impairment | Major Depressive Disorder | tDCS | Transcranial Direct Current Stimulation | Alzheimer's DementiaCanada